Kardigan, Inc.
Kardigan is a biopharmaceutical company based in Princeton, New Jersey, that develops medicines for cardiovascular conditions. Its pipeline targets processes underlying cardiovascular disease, including cardiomyopathies that can lead to heart failure. The company combines artificial intelligence, real-world clinical information, and cardiac analytics to guide study design, patient screening, and efficacy monitoring. Its drug development work also uses Prolaio’s cardiovascular data and analytics platform.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $KARD in the last 30 days.
See all $KARD insider activity →Leerink Partners kept Kardigan at Outperform but reduced its price target to $36 from $37, a 2.7% cut. The new target suggests a 155.0% upside from the Nov 12 close of $14.12. Recent analyst notes on Kardigan have price targets ranging from $42 to $50.
Kardigan, Inc. (KARD) reported Q3 GAAP EPS of -$0.64, exceeding estimates by $0.43. R&D expenses rose to $64.36M, up from $49.14M in Q3 2025, while G&A expenses increased to $22.25M from $9.94M.
Kardigan reported a Q3 2026 net loss of $58.6M, down from $60.2M a year earlier, with $591.4M in cash. R&D expenses rose to $64.4M. The company completed Phase 2b trials for danicamtiv and ataciguat, expecting 2027 results. Cash runway supports Phase 3 trials. KARD added Kristin Reinke to its board.
Over the past 7 days, AlphAI's AI scored 4 news stories mentioning KARD (Kardigan, Inc.). Coverage has skewed bullish: 2 bullish, 2 neutral, and 0 bearish.
Recent KARD coverage spans financial news and earnings.
Leerink Partners kept Kardigan at Outperform but reduced its price target to $36 from $37, a 2.7% cut. The new target suggests a 155.0% upside from the Nov 12 close of $14.12. Recent analyst notes on Kardigan have price targets ranging from $42 to $50.
The earnings beat may lift the stock despite a loss, as investors price in better-than-expected performance.
Earnings miss with reduced loss but high cash gives modest upside potential; investors may weigh cash position vs ongoing trial spend.
Enrollment milestones reduce clinical risk and extend cash runway, likely supporting short‑term price upside.
Kardigan completed enrollment in its Phase 2b KATALYST-AV trial for ataciguat in aortic stenosis. The primary endpoint, aortic valve calcium, will be assessed at Week 48, with topline data expected in 2H 2027. Real-world data informed patient selection and trial design. The company will host an investor webcast on November 7, 2026.
AlphAI scores every news story that mentions KARD with an AI model for sentiment and relevance, and aggregates insider trades from Kardigan, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Leerink Partners kept Kardigan at Outperform but reduced its price target to $36 from $37, a 2.7% cut. The new target suggests a 155.0% upside from the Nov 12 close of $14.12. Recent analyst notes on Kardigan have price targets ranging from $42 to $50.
Kardigan, Inc. (KARD) reported Q3 GAAP EPS of -$0.64, exceeding estimates by $0.43. R&D expenses rose to $64.36M, up from $49.14M in Q3 2025, while G&A expenses increased to $22.25M from $9.94M.
Kardigan reported a Q3 2026 net loss of $58.6M, down from $60.2M a year earlier, with $591.4M in cash. R&D expenses rose to $64.4M. The company completed Phase 2b trials for danicamtiv and ataciguat, expecting 2027 results. Cash runway supports Phase 3 trials. KARD added Kristin Reinke to its board.
Kardigan, Inc. (KARD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 PRESS RELEASE Kardigan Reports Third Quarter 2026 Financial Results and Recent Business Updates Completed enrollment in Cohort 2 of Phase 2b danicamtiv KINSHIP-DCM trial, topline data expected in 2Q 2027; Phase 3 enrollment underway in both cohorts Completed enrollme
Kardigan completed enrollment in its Phase 2b KATALYST-AV trial for ataciguat in aortic stenosis. The primary endpoint, aortic valve calcium, will be assessed at Week 48, with topline data expected in 2H 2027. Real-world data informed patient selection and trial design. The company will host an investor webcast on November 7, 2026.
H.C. Wainwright initiated coverage on Kardigan Inc. (NASDAQ:KARD) with a buy rating and $42 price target, citing strong management, market potential, and clinical data. The stock has a $1.34B market cap and trades at $14.32. Other analysts also gave positive ratings with varying price targets. Kardigan's pipeline includes three late-stage cardiovascular drugs.
Analysts made several calls on Wall Street, including Bank of America raising Microsoft's price target to $630, Goldman Sachs reiterating Apple as buy, Morgan Stanley naming Carvana a top pick, and JPMorgan initiating Palantir as overweight. Other notable updates include upgrades for Hilton, Oracle, and Wintrust Financial, while Alphabet was downgraded by Citizens. Analysts also initiated coverage on companies like Rubrik, Fervo Energy, Ormat Technologies, and Absci, with mixed ratings.
Alphabet (GOOGL) fell 10% after missing revenue expectations, while Microsoft (MSFT) rose 3% on strong earnings. Analysts upgraded eBay (EBAY) to $106, Hilton (HLT) to $421, and downgraded Alphabet, Boston Scientific (BSX), and Fortinet (FTNT). Bitcoin traded flat near $80,500-$81,000. Fed held rates steady, but may raise 25bps in December. Brent Crude and WTI oil rose, gold gained 0.17%.
Baird initiated coverage on Kardigan Inc (NASDAQ:KARD) with an Outperform rating and a $43 price target, citing its precision-cardiology portfolio. The stock is near its 52-week low of $12.23. Analysts highlight danicamtiv's potential and other pipeline programs. Kardigan has a Strong Buy consensus rating with targets ranging from $25 to $46. The company expects Phase 2 readouts in early 2027.
William Blair initiated coverage on Kardigan Inc (NASDAQ:KARD) with an Outperform rating and a $38 price target, citing potential upside of 174%. The firm highlighted the company's cardiovascular pipeline and experienced team. UBS also initiated coverage with a Buy rating and a $25 target. Kardigan's stock currently trades at $13.88, with Phase II readouts expected in 2027.
